Market

Dyne Therapeutics Announces New Long-Term Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through

Dyne Therapeutics Announces New Long-Term Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through
Read More

Related Posts

South Korea's pension fund logs record 15% investment return in 2024

South Korea's pension fund logs record 15% investment r...

Canada watchdog probing X's use of personal data in AI models' training

Canada watchdog probing X's use of personal data in AI ...

Why Nvidia earnings report is good news for its Big Tech rivals

Why Nvidia earnings report is good news for its Big Tec...

Dollar firms as Trump's tariffs loom, yen set for monthly gain

Dollar firms as Trump's tariffs loom, yen set for month...

Factbox-Key economic targets expected to be approved by China's parliament

Factbox-Key economic targets expected to be approved by...

Rocket Lab makes ‘bold’ satellite move, but shares slide on weak outlook

Rocket Lab makes ‘bold’ satellite move, but shares slid...